miR-25-3p在40例子宫内膜腺癌组织中的表达及对KLE细胞生物学功能的影响

doi:10.6040/j.issn.1671-7554.0.2020.0906

摘要/Abstract

摘要： 目的探讨miR-25-3p在子宫内膜腺癌组织中的表达及其对KLE细胞增殖、迁移、侵袭、凋亡的影响。方法选取2018年1月至12月在河北医科大学第四医院妇科行手术治疗的子宫内膜腺癌患者40例,采用Real-time PCR方法检测癌和癌旁正常组织中miR-25-3p的表达水平;应用细胞转染技术将miR-25-3p模拟物转染至子宫内膜腺癌细胞KLE中,转染后分为过表达组和对照组;采用Real-time PCR方法检测转染后两组KLE细胞中miR-25-3p的表达水平;分别应用流式细胞术、Transwell试验、基质胶试验及流式细胞Annexin v-PI 双染实验检测两组细胞的增殖、迁移、侵袭及凋亡能力。结果 miR-25-3p在40例子宫内膜腺癌和癌旁组织中的相对表达量分别为0.38±0.91、0.17±0.51,癌组织表达高于癌旁组织,差异有统计学意义(t=12.28,P=0.003);增殖实验检测结果显示,两组增殖指数分别为(59.41±0.78)%、(40.69±0.78)%,过表达组高于对照组,差异有统计学意义(各期两组间均值差异均有统计学意义: G0G1 期t=12.504, P<0.001; S 期t=6.902, P=0.020; G2M期t=4.203, P=0.014;PI期t=12.475,P<0.001);迁移实验检测结果显示,两组迁移细胞个数分别为(28.54±1.73)个、(19.21±1.62)个,过表达组高于对照组,差异有统计学意义(t=8.404, P=0.001);侵袭实验检测结果显示,两组的侵袭细胞个数分别为(36.66±1.53)个、(17.66±1.53)个,过表达组高于对照组,差异有统计学意义(t=15.234, P<0.001);凋亡检测结果显示,两组的细胞凋亡率分别为(2.75±0.58)%、(4.81±0.31)%, 过表达组低于对照组,差异有统计学意义(t=5.443, P=0.006)。结论 miR-25-3p在子宫内膜腺癌组织中呈高表达。过表达miR-25-3p可能促进子宫内膜腺癌细胞KLE的增殖、迁移和侵袭,抑制细胞的凋亡。

关键词: miR-25-3p, 子宫内膜腺癌, 增殖, 迁移, 侵袭, 细胞凋亡

Abstract: Objective To investigate the expression of miR-25-3p in endometrial cancer tissues, and to explore its effects on the proliferation, migration, invasion and apoptosis of KLE cells. Methods A total of 40 patients with endometrial cancer treated during Jan. and Dec. 2018 were enrolled. The cancer tissues and adjacent tissues were collected, and the miR-25-3p expressions were detected with Real-time PCR. After KLE cells were transfected with miR-25-3p mimics, they were divided into overexpression group and control group, whose miR-25-3p expressions were detected with Real-time PCR. The proliferation, migration, invasion and apoptosis of the two groups of KLE cells were detected with flow cytometry, Transwell assay, matrigel invasion assay, and Annexin v-PI double staining assay, respectively. Results The expression of miR-25-3p was 0.38±0.91 in cancer tissues and 0.17±0.51 in the adjacent tissues, and the difference was statistically significant (t=12.28, P=0.003). Flow cytometry showed the proliferation index was(59.41±0.78)% in the overexpression group and(40.69±0.78)% in the control group, and the difference was statistically significant(G0G1 phase: t=12.504, P<0.001; S phase: t=6.902, P=0.020; G2M phase: t=4.203, P=0.014; PI phase: t=12.475, P<0.001). Transwell assay showed the number of migration cells was 28.54±1.73 in the overexpression group and 19.21±1.62 in the control group, and the difference was statistically significant(t=8.404, P=0.001). Matrigel invasion assay showed the number of invasion cells was 36.66±1.53 in the overexpression group and 17.66±1.53 in the control group, and the difference was statistically significant(t=15.234, P<0.001). Annexin v-PI double staining assay showed the apoptosis rate was(2.75±0.58)% in the overexpression group and(4.81±0.31)% in the control group, and the difference was statistically significant(t=5.443, P=0.006). Conclusion miR-25-3p is highly expressed in endometrial cancer tissues. Overexpression of miR-25-3p promotes the proliferation, migration and invasion but inhibits the apoptosis of KLE cells.

Key words: miR-25-3p, Endometrial cancer, Proliferation, Migration, Invasion, Apoptosis

中图分类号:

R737.33

史丽,马静,赵喜娃,关英霞,赵连梅,单保恩. miR-25-3p在40例子宫内膜腺癌组织中的表达及对KLE细胞生物学功能的影响[J]. 山东大学学报 (医学版), 2020, 58(12): 86-91.

SHI Li, MA Jing, ZHAO Xiwa, GUAN Yingxia, ZHAO Lianmei, SHAN Baoen. Expression and function of miR-25-3p in endometrial cancer[J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 86-91.

参考文献

[1] Li BL, Wan XP. The role of lncRNAs in the development of endometrial carcinoma(review)[J]. Oncol Lett, 2018,16(3): 3424-3429.
[2] Xiang J, Hang JB, Che JM, et al. miR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7 [J]. Int J Clin Exp Pathol, 2015, 8(8): 9147-9153.
[3] Zhou J, Zhou J, Wang W, et al. The polymorphism in miR-25 attenuated the oncogenic function in gastric cancer [J]. Tumor Biology, 2016, 37(4): 5515-5520.
[4] Liu Y, Cai QY, Bao PP, et al. Tumor tissue micro RNA expression in association with triple-negative breast cancer outcome [J]. Breast Cancer Res, 2015, 152(1): 183-191.
[5] Ning L, Zhang M, Zhu Q, et al. miR-25-3p inhibition impairs tumorigenesis and invasion in gastric cancer cells in vitro and in vivo [J]. Bioengineered, 2020, 11(1): 81-90.
[6] Liu G, Kang X, Guo P, et al. miR-25-3p promotes proliferation and inhibits autophagy of renal cells in polycystic kidney mice by regulating ATG14-Beclin 1 [J]. Ren Fail, 2020, 42(1): 333-342.
[7] Zhan J, Tong J, Fu Q. Long non-coding RNA LINC00858 promotes TP53-wild-type colorectal cancer progression by regulating the microRNA-25-3p/SMAD7 axis [J]. Oncol Rep, 2020, 43(4): 1267-1277.
[8] Komatsu S, Ichikawa D, Hirajima S, et al. Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma [J]. Br J Cancer, 2014, 111(8): 1614-1624.
[9] AL Smith, R Iwanaga, DJ Drasin, et al. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer [J]. Oncogene, 2012, 31(50): 5162-5171.
[10] Fadaka AO, Klein A, Pretorius A. In solico identification of microRNAs as candidate colorectal cancer biomarkers [J]. Tumor Biol, 2019, 41(11): 1-15.
[11] Fujiwara T, Uotani K, Yoshida A, et al. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma [J]. Oncotarget, 2017, 8(20): 33375-33392.
[12] Leite KRM, Tomiyama A, Reis ST, et al. MicroRNA expression profiles in the progression of prostate cancer - from high-grade prostate intraepithelial neoplasia to metastasis [J]. Urol Oncol, 2013, 31(6): 796-801.
[13] Bueno MJ, Perez DCI, Malumbres M. Control of cell proliferation pathways by micro RNAs [J]. Cell Cycle, 2008, 7(20): 3143-3148.
[14] Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis [J]. Eur J Cancer, 2011, 47(8): 1127-1137.
[15] 梁静, 张贵宇, 马本红. 子宫内膜样腺癌组织中mircroRNA差异表达分析[J]. 山东大学学报(医学版), 2011, 49(8): 90-95. LIANG Jing, ZHANG Guiyu, MA Benhong. Differential expression analysis of mircroRNA in endometrioid adenocarcinoma [J]. Journal of Shandong University(Health Sciences), 2011, 49(8): 90-95.
[16] Li Q, Zou C, Zou C, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7 [J]. Cancer Lett, 2013,335(1): 168-174.
[17] Marchi S, Lupini L, Patergnani S, et al. Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related miR-25 [J]. Commun Integr Biol, 2012, 23(1): 58-63.
[18] Zhang H, Zuo Z, Lu X, et al. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer [J]. Oncol Rep, 2012, 27(2): 594-598.
[19] Hao CY, Duan HB,Li H, et al. Knockdown of MRPL42 suppresses glioma cell proliferation by inducing cell cycle arrest and apoptosis [J]. Biosci Rep, 2018, 38(2): 59-67.
[20] Shen FZ, Chang HG, Gao GJ, et al. Long noncoding RNA FOXD2 ASl promotes glioma malignancy andtumorigenesis via targeting miR-185-5p/CCND2 axis [J]. J Cell Biochem, 2019, 120(6): 9324-9336.
[21] Li F, Jin D, Tang C, et al. CEP55 promotes cell proliferation and inhibits apoptosis via the P13K/Akt/p21 signaling pathway in human glioma U251 ceils [J]. Oncol Lett, 2018, 15(4): 4789-4796.
[22] Hong Xin M, Lei Z, Jingna R, et al. Myricetin inhibits migration and invasion of hepatocellular carcinoma MHCC97H cell line by inhibiting the EMT process [J]. Oncol Lett, 2019, 18(6): 6614-6620.
[23] Fernanda L, Jose TM, Castellon Enrique A, et al. Secreted protein acidic and rich in cysteine(SPARC)induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer [J]. Asian J Androl, 2019, 21(6): 557-564.
[24] Croce CM, Casadei L, Calore F, et al. Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression [J]. Cancer Res, 2017, 77(14): 3846-3856.
[25] Peng G, Yang C, Liu Y, et al. miR-25-3p promotes glioma cell proliferation and migration by targeting FBXW7 and DKK3 [J]. Exp Ther Med, 2019, 8(1): 769-778.

相关文章 15

[1]	王晓磊张海涛张辉郭成浩. 舒血宁注射液对高碘致培养血管内皮细胞损伤的保护作用[J]. 山东大学学报(医学版), 2209, 47(6): 38-.
[2]	鹿向东杨伟徐广明曲元明. 脑膜瘤中PPAR-γ的表达及曲格列酮对脑膜瘤培养细胞生长的影响[J]. 山东大学学报(医学版), 2209, 47(6): 65-.
[3]	孙薏丰,高玉,梁永媛,高杨. CPLX2在30例肝癌组织的表达及其对体外细胞增殖与侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 34-39.
[4]	李涵,付婷婷,张磊,延冰,孙涛,郭峰,尹晓. 过氧化物酶增殖物激活受体γ激动剂对24例肥胖症患者米色脂肪细胞分化的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 8-13.
[5]	李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38-46.
[6]	马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32-37.
[7]	付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[8]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[9]	张晓璐,王丽莉,陈凯明,娄宪芝,张曼. 组蛋白去乙酰化酶SIRT1经Toll样受体4途径对巨噬细胞凋亡的调控[J]. 山东大学学报 (医学版), 2020, 58(12): 8-14.
[10]	李昌达,史永军,林彦良. 27-羟基胆固醇与胆固醇对裸鼠食管鳞癌和人食管癌细胞增殖的影响[J]. 山东大学学报 (医学版), 2020, 58(11): 45-52.
[11]	洪甲庚,聂洋洋,苏国强. 丙泊酚对结肠癌细胞增殖、迁移及Wnt1和β-catenin表达的影响[J]. 山东大学学报 (医学版), 2020, 58(11): 53-58.
[12]	王凯民,谭娟娟,严志强,李志强. Sirtuin在低氧诱导人脐带间充质干细胞增殖中的作用[J]. 山东大学学报（医学版）, 2017, 55(7): 23-30.
[13]	郭贺贺,孙志强,刘艳娟,刘奕晨,李广,郑方. 去甲斑蝥素对骨髓瘤U266细胞Notch信号通路表达的影响[J]. 山东大学学报（医学版）, 2017, 55(3): 32-37.
[14]	史培堃,曾贝妮,吴伟芳,胡晓燕,马天加,周亚滨. Keap1在肾细胞癌中的表达及其作用[J]. 山东大学学报（医学版）, 2017, 55(3): 94-99.
[15]	孙泽雨,陈颖,林家香,刘娟,赵蔚明. 磷脂酰肌醇-4-磷酸酶II型对宫颈癌细胞增殖及凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(11): 1-6.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed